A tool compound strips the DNA-repair proteins tumors use to dodge PARP inhibitors. Preclinical only — but the gap between treated and control animals is the story.
The trial failed by its own pre-registered measure. What the investigators chose to highlight in media appearances is worth examining closely.
The hearing didn't produce answers. It produced a paper trail — and a list of names who now have to respond.
Twenty-seven years of regulatory lag, in one line.
Antibodies that neutralize fentanyl before it crosses the blood-brain barrier. The question the trial has to answer: what happens when someone with the vaccine encounters a variant opioid?
If the amyloid hypothesis is wrong, clearing plaques won't help. A new compound takes a different upstream target — and the early numbers are interesting.
Omega-3 supplementation shifted T-cell populations toward a regulatory phenotype in a NOD mouse model. Not humans, not yet — but the mechanism is worth tracking.
A single study with a sample size and follow-up period that wouldn't pass peer review at a nutrition journal is driving a national retail policy. The receipts are here.
The hearing didn't produce answers. It produced a paper trail — and a list of names who now have to respond.
Same CPT code, same analyzer, same blood draw — and a 12x price difference depending on who's billing. We obtained the itemized claims.
Defense-funded research into vortex combustion turns out to have a cleaner burn profile than flat-surface ignition. The environmental implications are not small.